Skip to main
  1. Stocks
  2. Summit Therapeutics
  3. Forecast
SMMT

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics (SMMT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 18%
Hold 27%
Sell 9%
Strong Sell 0%

Bulls say

Summit Therapeutics is viewed favorably because the clinical data for ivonescimab continue to strengthen, with HARMONi-2 improving to an OS HR of 0.73 at 234 deaths from 0.777 at 157 deaths and showing median OS of 30.75 versus 22.57 months, which eases concerns about the earlier survival readout. The company’s case is further supported by the competitive context, since its efficacy profile is being weighed against sac-TMT + pembrolizumab, which posted a 0.35 PFS HR and 70.2% ORR versus 0.51 and 50.0% for ivonescimab. Although sac-TMT’s early OS HR of 0.55 at 87 deaths still needs maturation, HARMONi-3’s final PFS/interim OS in 2H26 is the key global test.

Bears say

Summit Therapeutics is viewed negatively because its ivonescimab program still lacks the mature, global evidence needed to justify premium expectations, while the company’s China data are showing less durability than early headlines implied. H-6’s PFS hazard ratio worsened from 0.60 at 10.28 months to 0.72 at 17.02 months, H-2 still shows immature OS with an HR of about 0.78, and H-3 did not accelerate regulatory timing despite added interim review. The outlook is further pressured by Merck’s sac-TMT and MK-2010 options, which limit differentiation and raise combination toxicity concerns, with Grade ≥3 TRAEs of 29.4% versus 15.6% in HARMONi-2 and 55.3% versus 31.4% with sac-TMT plus pembrolizumab.

Summit Therapeutics (SMMT) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 18% recommend Buy, 27% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction

Get the latest Summit Therapeutics (SMMT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Summit Therapeutics (SMMT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Summit Therapeutics (SMMT) Forecast

Analysts have given Summit Therapeutics (SMMT) a Buy based on their latest research and market trends.

According to 11 analysts, Summit Therapeutics (SMMT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Summit Therapeutics (SMMT)


Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction

Get the latest Summit Therapeutics (SMMT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Summit Therapeutics (SMMT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SMMT stock data and trends